ISSN: 1859 - 2872
Comparison of improvement in quality of life between biological and conventional treatments for psoriasis vulgaris
Main Article Content
Keywords
Abstract
Objective: To compare the improvement in quality of life between biological and conventional treatments for psoriasis vulgaris. Subject and method: A cross-sectional study in 31 patients treated with biological agents (secukinumab and ustekinumab) and 31 patients treated with conventional treatments. Vietnamese-standardized DLQI was measured in both two groups at baseline, 1 month (T1), and 3 months (T3) after treatment. Result: Age, gender, occupation, age of onset and BMI were similar between the two groups. PASI in group 1 was significantly higher than that in group 2 (27.19 ± 9.54 vs 16.42 ± 7.76, respectively). At T1 and T3, the PASI score in group 1 was significantly improved compared to group 2 and the difference in both groups was statistically significant. The correlation between DLQI and PASI in group 1 was statistically significant at T0 (p=0.02) and T3 (p<0.0001). DLQI at T0 of group 1 (20.65 ± 6.41) was higher than that of group 2 (9.55 ± 6.45) (p<0.001). At T1 and T3, DLQI score in group 2 was almost static, while that in group 1 decreased significantly (9.48 ± 4.22 vs 3.97 ± 3.23, respectively) (p<0.001). Conclusion: The psoriasis patients treated with biologic agents had better DLQI improvement. Biological agents may be a good treatment option for the improvement in quality of life.
Keywords: Psoriasis, biological agents, conventional treatments, quality of life.
Article Details
References
2. Rapp SR et al (1999) Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 41(3-1): 401-407.
3. Takeshita J et al (2017) Psoriasis and comorbid diseases: Epidemiology. J Am Acad Dermatol 76(3): 377-390.
4. Korte J et al (2004) Quality of life in patients with psoriasis: A systematic literature review. J Investig Dermatol Symp Proc 9(2): 140-147.
5. Finlay AY, Khan GK (1994) Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use. Clin Exp Dermatol 19(3): 210-216.
6. Hagg D et al (2015) Decision for biological treatment in real life is more strongly associated with the Psoriasis Area and Severity Index (PASI) than with the Dermatology Life Quality Index (DLQI). J Eur Acad Dermatol Venereol 29(3): 452-456.
7. Poor AK et al (2018) Is the DLQI appropriate for medical decision-making in psoriasis patients? Arch Dermatol Res 310(1): 47-55.
8. Ali FM et al (2017) A systematic review of the use of quality-of-life instruments in randomized controlled trials for psoriasis. Br J Dermatol 176(3): 577-593.
9. Hjuler KF, Iversen L, Rasmussen MK, Kofoed K, Skov L, Zachariae (2019) Localisation of treatment-resistant areas in patients on biologics. Br J Dermatol. 181(2): 332-337.
10. Leman J et al (2019) The real world impact of adalimumab on quality of life and the physical and psychological effects of moderate-to-severe psoriasis: A UK prospective, multicenter, observational study. J Dermatolog Treat 21: 1-34.
Article Sidebar
